Junshi Biosciences Announces Collaboration with Dr. Reddy's to Develop and Commercialize Toripalimab in 21 Countries

SHANGHAI, China, May 07, 2023 -- Shanghai Junshi Biosciences Co., Ltd announced a collaboration with Dr. Reddy’s Laboratories Limited to develop and commercialize toripalimab, the anti-PD-1... | May 7, 2023

Related Keywords

Uzbekistan ,Uruguay ,Panama ,Beijing ,China ,United Kingdom ,Colombia ,Suzhou ,Jiangsu ,Bombay ,Maharashtra ,India ,New Zealand ,South Africa ,Argentina ,Peru ,Shanghai ,Australia ,Brazil ,Hyderabad ,Andhra Pradesh ,Maryland ,United States ,Mexico ,Chile ,San Francisco ,California ,Guangzhou ,Guangdong ,Chinese ,America ,Zhi Li ,Junshi Biosciences ,Junshi Bioscience ,National Stock Exchange Of India ,York Stock Exchange ,Good Health Cant Wait ,Ir Team ,National Reimbursement Drug List ,Bombay Stock Exchange ,Pr Team ,New York Stock Exchange ,Regulatory Agency ,Shanghai Junshi Biosciences Co Ltd ,Drug Administration ,European Medicines Agency ,Reddy Laboratories Limited Dr ,Laboratories Limited ,Latin America ,For Global ,Chief Executive Officer ,Branded Markets ,Emerging Markets ,Southeast Asia ,Biologics License Application ,Breakthrough Therapy ,Fast Track ,Orphan Drug ,National Stock Exchange ,Sustainability Report ,Emergency Use Authorizations ,Shanghai Junshi Biosciences Co ,Td Stock Exchange ,News ,Information ,Press Release ,Bay ,023 ,Junshi ,Iosciences ,Td ,Nnounced ,Collaboration ,Ith ,Laboratories ,Imited ,O ,Evelop ,End ,Ommercialize ,He 1877 Cne100003ff7 ,